Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 785 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gene Expression Clear all

Conditions: Breast Pumping
Interventions: Ameda Pearl breast pump; Device
Lead sponsor: Ameda, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Leukemia
Interventions: choline magnesium trisalicylate, Dexamethasone; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Total-body Irradiation, Hematopoietic Stem Cell Transplant
Interventions: Not listed
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 2 Years to 21 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Ovarian Neoplasms
Interventions: removal of ovarian vessels; Procedure
Lead sponsor: United States Department of Defense; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Gastric Cancer, Peritoneal Carcinomatosis
Interventions: Cisplatin, Mitomycin; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Neoplasms, Gastric Neoplasm, Solid Tumors
Interventions: ARX788; Drug
Lead sponsor: Ambrx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 5
States / cities: Los Angeles, California • Santa Monica, California • St Louis, Missouri + 2 more

Conditions: Epithelial Carcinoma, Solid Tumor
Interventions: SYN125, SYN004; Biological
Lead sponsor: Synermore Biologics Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Fairway, Kansas • Brownstown, Michigan • St Louis, Missouri + 1 more

Conditions: Wounds and Injuries
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Prostatic Neoplasms
Interventions: Standard NCCN counseling, Standard NCCN counseling and Oncotype DX results; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: Up to 76 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Chicago, Illinois

Conditions: Inflammation, Mental Health Wellness 1
Interventions: Self-Focused Acts of Kindness Intervention, Other-Focused Acts of Kindness Intervention, Daily Reports; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 14 Years to 17 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Invasive Breast Cancer
Interventions: [18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Glioblastoma
Interventions: 18F-FluorThanatrace; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 22 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Migraine Disorders
Interventions: Emotional Awareness and Expression Therapy (EAET); Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Melanoma (Skin)
Interventions: comparative genomic hybridization, cytogenetic analysis, fluorescence in situ hybridization, immunohistochemistry staining method; Genetic · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 27
States / cities: Chicago, Illinois • Cedar Rapids, Iowa • Boston, Massachusetts + 17 more

Conditions: Pain, Inflammation
Interventions: Ibuprofen, Placebo tablet; Drug
Lead sponsor: Martin Angst; Other
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Tuberculosis
Interventions: Bronchoalveolar lavages and venipunctures only; Other
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Premature Birth, Breastmilk Collection, Postnatal Growth Restriction
Interventions: Targeted Fortification, Enfamil Liquid Human Milk Fortifier; Dietary Supplement
Lead sponsor: Loma Linda University; Other
Eligibility: Not listed
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Triple Negative Breast Cancer
Interventions: PET imaging; Diagnostic Test
Lead sponsor: Ahmad Shariftabrizi; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Recurrent Prostate Cancer
Interventions: Biopsy; Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Neoplasms
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Female only
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity, Morbid Obesity, Weight Loss
Interventions: Gastric Bypass Surgery; Procedure
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer, Hematopoietic Stem Cell Transplantation
Interventions: Emotional expression; Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Non Small Cell Lung Cancer, Cancer
Interventions: Venetoclax, Pembrolizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 39
States / cities: Birmingham, Alabama • Tucson, Arizona • Santa Rosa, California + 31 more

Conditions: Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: Tipifarnib, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 65 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 7
States / cities: Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 2 more

Search by objective public record fields.

Clinical Validation of the Ameda Pearl - An Electric, Hospital Grade, Multi-User Breast Pump

Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate

Radiation Biodosimetry in Children Undergoing Total Body Irradiation

Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions

Gene Expression Profiles in Healing and Non-Healing Wounds

Engaging Newly Diagnosed Men About Cancer Treatment Options

Adolescent Acts of Kindness Intervention

FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer

18F-FluorThanatrace (PET/CT) in Glioblastoma

Emotional Awareness and Expression Therapy (EAET) as a Novel Migraine Treatment

Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma

Study of Experimental Models of Pain and Inflammation.

Expression of Tuberculosis in the Lung

Targeted Nutrition for Moderate to Late Preterm Infants

Breast Cancer PSMA PET

Tumor Microenvironment Analysis of Prostate Cancer Metastasis

Genetic and Protein Profiling in Normal and Cancerous Breast Tissue

Studies of Biological Changes Related to Weight Loss After Gastric Bypass Surgery

Spouses/Partners Expressing Their Thoughts After Transplant

A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia